Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Antimicrobial resistance in Neisseria gonorrhoeae David Lewis National Institute for Communicable Diseases National Health Laboratory Service Johannesburg South Africa NHLS NICD NHLS NICD The First World War • Gonorrhoea control was based on: - personal hygiene lectures - weekly medical ‘visual’ examination of CSWs • Venereal ablution rooms established in all barracks (1916) and soldiers at risk were under order to attend within 24 hours of potential exposure to N. gonorrhoeae • Self-administered regimen: - wash genitals with soap and water - irrigate the urethra with KMnO4 (“pinky panky”) - apply calomel ointment to the whole area • Prophylactic “packets” (1917) - calomel ointment to apply to the genitals - tube of argyrol for the urethra (after coitus) - condoms Urethral dilators c. 1900 From Valentine (1900) “The irrigation treatment of gonorrhoea” “Kollmann’s ingeniousness seems to have no limit” Sulphonamides • Gerhard Domagk reported that Prontosil was curative against haemolytic streptococci in animals (1935) - he later used it with success in humans • Prontosil released sulphanilamide - easily manufactured • First studies using sulphanilamide in gonorrhoea came from Germany, UK and USA (1937) • Cure rates for gonorrhoea rose to 80-90% • By 1944, treatment failures were common Penicillin • Alexander Fleming published his discovery of penicillin in 1929 • Cecil Paine treated two babies with gonococcal conjunctivitis with crude extract of Penicillium notatum in 1930 • Penicillin was first used to treat gonococcal urethritis in 1943 (USA) – mainly troops • Cure rates with IM penicillin were >95% MIC drift for penicillin against Neisseria gonorrhoeae, USA (1955-69) Initial studies in men undertaken to determine the minimal amounts of drug and the shortest treatment period which would produce an acceptable cure rate (20,000 U 3hrly x 6 doses = 72 mg; 15 hours treatment period) 0.05 U = 0.03 μg 0.5 U = 0.3 μg Slyke et al., Am. J. Pub. Health. 1943;33:1392-1394 Martin et al. J. Infect. Dis., 1970:122:459-461 Slide courtesy of David Livermore, Health Protection Agency, UK (modified) Chromosomally-mediated resistance • By mid 1950s, several reports of decreased susceptibility to penicillin • Chromosomal resistance reported in 1958 Low-level, multiple step resistance penA - 4-8 fold increase in penicillin MICs - lowered affinity for PBP2 - shift to PBP1 target mtr - low level resistance to several Abs (Pen, Ery and Tet) - altered cell envelope with decreased permeability penB - encodes for PorB1-b, porin - 4-fold increase in penicillin and tetracycline MIC with mtr pen A + mtr + penB gives 120-fold increase in penicillin MIC ponA - lowered affinity for PBP-1 penC - efflux/permeability mechanisim (penicillin and tetracyclines) Plasmid-mediated resistance • First reported independently in UK and USA in 1976 • The 3.2 MDa African and 4.4 MDa Asian plasmids are identical except for a 2.1 kb deletion • Require the 24.5 MDa conjugative plasmid for transfer • More plasmids were identified from the mid-1980s onwards: Toronto 3.05 MDa , Rio 2.9 MDa, Nimes 4.0 MDa and New Zealand 6.5 MDa 100 PPNG prevalence (%) 90 80 70 1985 60 1990 50 1995 40 2000 30 20 2005 10 0 PPNG 1985 1990 1995 2000 2005 39 44 67 75 87 Rise in PPNG prevalence in Cameroon (1985-2005) Manuel de formation des prestataires de soins sur la prise en charge syndromique des IST au Cameroun. Ministry of Public Health, April 2007. Tetracycline • Tetracycline was designed by chemical alteration of a microbial product (1952) • Chromosomal resistance soon followed (rpsJ + penB + mtr) • Plasmid-mediated resistance (TRNG), with MIC > 10 mg/L, first appeared in the Netherlands (1985) and USA (1986) • Dutch and American TRNG strains had different phenotypes 80 Data from Gauteng Province for 210 N. gonorrhoeae isolates surveyed in 2008 Prevalence (%) 70 60 50 76% 40 30 Dutch plasmid 20 10 24% American plasmid 0 TRNG • CMTRNG Intermediate Susceptible Tetracycline resistance is now unacceptably high in most parts of the world STI Reference Centre, National Institute for Communicable Disease, South Africa Gentamicin • Gentamicin 240 mg i.m. has been used as national anti-gonococcal first-line therapy in Malawi since 1993 • Prescribed together with doxycycline in syndromic management • No standard MIC that defines resistance • Recent surveillance data from Malawi (2007) demonstrate that 100% of isolates tested (n= 100) are susceptible based on agar dilution results (MIC ≤ 4 mg/l) • Injectable agents less liable to abuse Data courtesy of Irving Hoffman, University of North Carolina, USA Malawi surveillance studies have been performed through a collaboration between the University of North Carolina, the Kamuzu Central Hospital’s STI Clinic in Lilongwe and the Malawian Department of Health. Spectinomycin 45 Pen • Developed and marketed specifically for the treatment of gonorrhoea • Narrow MIC range related to efficacy • Resistance was described in 1973 and widespread by the early 1980s Spectinomycin 40 Penicillin 35 Resistance (%) 30 25 Penicillin • Spectinomycin Resistance due to mutation in spc locus - decreases sensitivity of 30S ribosomal subunit to spectinomycin 20 15 10 Spectinomycin 5 • Major outbreak of spectinomycin resistant gonorrhoea among US military in Korea in 1987 after only 6 years’ use • Still has a key role in selected cases 0 1980 1981 1982 1983 1984 1985 Year Boslego JW et al., New Eng. J. Med. 1987;317:272-278 Quinolones • Compared to nalidixic acid, fluoroquinolones have 100 x greater activity and broader spectrum by virtue of a fluorine atom at C6 • Clinical failure of single dose 250mg ciprofloxacin was first reported in London in 1990 – failures with the 500mg dose soon followed • Resistance in N. gonorrhoeae is associated with point mutations resulting in amino acid changes in: a) b) • the A subunit (GyrA) of the DNA gyrase the parC-encoded subunit of topoisomerase IV Many countries have now stopped using quinolones to treat gonorrhoea Rise in ciprofloxacin resistant gonorrhoea WHO Western Pacific Region Prevalence of QRNG in the WHO Western Pacific Region 100 90 80 % resistance 70 Hong Kong 60 Japan 50 Phillipines 40 Singapore Australia 30 20 10 0 1997 1998 1999 2000 2001 2002 2003 2004 WHO Western Pacific Region Gonococcal Antimicrobial Surveillance Programme (GASP) Rise in ciprofloxacin resistant gonorrhoea South Africa (2004-2007) 35 32% Prevalence of Resistance (%) 30 29% 28% 25 2004 20 2005 15 10 17% 16% 2007 11% N/D 7% 5 0 Johannes burg 2006 Cape Town Lewis DA et al., Sex Transm. Infect. 2008;84:352-355 STI Reference Centre, National Institute for Communicable Disease, South Africa Association between sexual orientation and ciprofloxacin susceptibility profile GRASP and GISP survey data GRASP 2000-2008 GISP 2001-2007 The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) 2008, Health Protection Agency, UK Gonococcal Isolate Surveillance Project (GISP) Annual Report 2007, CDC, USA Association between HIV serostatus and ciprofloxacin susceptibility profile 2007 surveys in Cape Town and Johannesburg 120 100 N = 191 N = 75 80 57% Percentage (%) 60 71% HIV negative HIV positive 40 43% 20 29% 0 Susceptible Resistant Susceptibility profile to ciprofloxacin Lewis DA et al., Sex Transm. Infect. 2008;84:352-355 p = 0.034 Azithomycin • The 2g dose has significant G/I side-effects (better with ER formulation) • Isolates with reduced susceptibility have been identified since 1997 • Emerging resistance involves: - bacterial efflux systems (mtrRCDE operon, mef genes) - modification of ribosomal target (erm genes) - single nucleotide mutation in 23S rRNA gene • A cluster of 6 gonococcal isolates with high-level azithromycin resistance (MIC 4,096 mg/l) was detected in the UK in 2007 • Heterosexually acquired, patients not previously treated with azithromycin, identical on NG-MAST typing (ST-649) UK Health Protection Agency Report 2008;2(14);4 April Shift in GISP Azithomycin MICs (1992-2007) N.B. In 2005, there was a change in medium used in GISP laboratories which resulted in an observational shift in the MIC by one dilution The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) 2008, Health Protection Agency, UK Gonococcal Isolate Surveillance Project (GISP) Annual Report 2007, CDC, USA Reliable management options at present • I.M. Cetriaxone 125mg or 250 mg stat. • Oral Cefixime 400mg stat. • • • • Oral Cefpodoxime proxetil 200mg stat. I.M. Cefuroxime axetil 1g stat. Oral Cetfibuten 400 mg stat. Oral Cefdinir 300-600mg stat. • Oral Azithromycin 2g stat. • I.M. Spectinomycin 2g stat. Antibiotics used to treat GRASP and GISP patients for gonorrhoea 100 Antimicrobials used to treat GRASP patients: 2000-2008 Percentage of GRASP patients 90 Antimicrobials used to treat GISP patients: 1988-2007 n=14,647 80 70 60 50 40 30 20 10 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 Fluoroquinolones Cephalosporins Azithromycin Doxycycline Ampicillin Other Note: GRASP data include antimicrobial agents given simultaneously for chlamydial infection The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) 2008, Health Protection Agency, UK Gonococcal Isolate Surveillance Project (GISP) Annual Report 2007, CDC, USA Prevalence of resistance to antimicrobial agents in clinical gonococcal strains isolated in Central Japan, 1999-2002 Gonococcal Phenotype 1999-2000 N = 91 2001 N = 150 2002 N = 221 PPNG 1.1% 0.7% 0.5% TRNG (MIC ≥ 16mg/l) 2.2% 0.7% 0.5% CMRNG Pen (MIC ≥ 2mg/l) 2.2% 59.3% 73.3% CMRNG Tet (MIC ≥ 2mg/l) 11.0% 53.7% 68.8% QRNG Levofloxacin (MIC ≥ 1mg/l) 27.5% 53.3% 78.3% Cefixime decreased susceptibility (MIC ≥ 0.5mg/l) 0% 26.0% 30.3% Ceftriaxone decreased susceptibility (MIC ≥ 0.5mg/l) 0% 0% 0.9% Spectinomycin resistance (MIC ≥ 128mg/l) 0% 0.7% 0% Ito M et al., Antimicrob. Agents Chemother. 2004;48:3185-3187 Decreased susceptibility to cefixime • Mosaic penA genes, which encode PBP-2, cause these raised MICs • Some of the regions within these mosaic genes show homology to the penA genes of N. perflava (N. sicca), N. cinerea, N. flavescens and N. meningitidis Ito M et al., Antimicrob. Agents Chemother. 2005;49:137-143 • Recently, another mutation in the ponA gene, which encodes for PBP-1, has been identified in strains exhibiting decreased susceptibility to cefixime (Leu 421 to Pro 421) - less significant than the mosaic penA changes Takahata S et al., Antimicrob. Agents Chemother. 2006;50:3638-3645 Cefixime MIC (mg/l) and presence of the mosaic penA gene, Japan (2002-2005) 160 140 120 mosaic penA native 100 80 N = 621 60 40 20 0 Ochiai S et al., J. Clin. Micro. 2008;46:1804-1810 Critical parameters for β-lactam therapy • β-lactam efficacy depends on duration for which [free drug] exceeds MIC • Penicillin is 70-80% protein bound, so for gonorrhoea, ‘therapeutic time’ is: Total [penicillin] > 4 x MIC for 7-10 hours (i.e. more than two-fold dilutions higher) • Data from penicillin-based studies has been extrapolated to cephalosporins • Protein-binding and half-lives of cephalosporins differ • For cephalosporins, a ‘therapeutic time’ for at least 10 hours is required to eliminate ≥ 95% of N. gonorrhoeae infections Jaffe HW et al., Antimicrob. Agents Chemother. 1979;15:587-591 Deguchi T et al., J. Infect. Chemother. 2003;9:35-39 Cefixime MIC drift, GRASP (2008) 70% 60% 2004 2005 50% 2007 2008 2006 40% 30% 20% 10% 0% MIC (mg/L) 0.002 0.004 0.008 0.015 0.03 0.06 0.125 0.25 12% 10% 8% 6% 4% 2% 0% 0.06 2004 2005 2007 2008 0.125 2006 0.25 MIC (mg/L) Slide courtesy of David Livermore, Health Protection Agency, UK (modified) The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) 2008, Health Protection Agency, UK Ceftriaxone MIC drift, GRASP (2008) MIC (mg/L) Slide courtesy of David Livermore, Health Protection Agency, UK The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) 2008, Health Protection Agency, UK Effect of prescribing cephalosporins on ciprofloxacin resistance (UK) Antimicrobial prescribing practice 2003 to 2008 Flouroquinolones % patients prescribed antimicrobial 90 30 Cephalosporins % Ciprofloxacin resistance (>=1mg/l) 25 80 70 20 60 50 15 40 % resistance 100 10 30 20 5 10 0 0 2003 2004 2005 2006 2007 2008 GRASP - The Gonococcal Resistance to Antimicrobials Surveillance Programme; sentinel data from 24 laboratories and 26 GUM clinics Slide courtesy of Catherine Ison, Health Protection Agency, UK The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) 2008, Health Protection Agency, UK Potential solutions Frapper fort, frapper vite (Ehrlich, 1913) • Cefixime for longer course: 3 days at 400 mg p.o. • Cefixime 800 mg, followed by 2 x 400 mg p.o. • Ceftriaxone 250 mg i.m., followed by 2 days cefixime p.o. Introduce firebreaks • Rotate cephalosporins / spectinomycin / azithromycin @ 2g • Treat males and females, or index and contacts, differently Slide courtesy of David Livermore, Health Protection Agency, UK (modified) Multi-drug and extensively drug resistant Neisseria gonorrhoeae (MDR-NG and XDR-NG) Class I: Antibiotics currently recommended for gonorrhoea • Injectable extended spectrum cephalosporins • Oral extended spectrum cephalosporins • Spectinomycin Class II: Antibiotics used less frequently, or proposed for more extensive use • • • • • Pencillins Fluoroquinolones Azithromycin Aminoglycosides Carbapenems Proposed definitions: MDR-NG: resistant to ≥ 1 class I antibiotic + ≥ 2 class II antibiotics XDR-NG: resistant to ≥ 2 class I antibiotics + ≥ 3 class II antibiotics Tapsall JW , Ndowa F, Lewis DA, Unemo M (manuscript submitted) Requirement for an integrated, comprehensive prevention strategy • Enhancement of national and international surveillance systems • Avoid further loss in culturing capability for N. gonorrhoeae • New strategies to prolong the usefulness of existing antimicrobials • Implement screening of high risk individuals • Ensure prompt and efficacious treatment is available • Tighter control on ‘open market’ antibiotic access & quality control of generics • Enhance proportion of sexual partners who receive treatment • Re-vitalise condom promotion and behavioural change strategies • Prioritise research on new therapeutic agents, e.g. anatomical site-specific clinical efficacy studies, pharmaceutical drug design • Higher priority for sexually transmitted disease control funding Conclusions • The gonococcus is has repeatedly evolved novel and effective resistance mechanisms • The creeping MICs of N. gonorrhoeae to cephalosporins is a prima facie case of emerging resistance • History repeats itself and human beings have a tendency not to learn • Treatment options are now very limited and we need to reconsider the wisdom of continuing to use single dose therapies • Extended regimens and firebreaks may assist in the short term • Multidrug therapy looks inevitable NHLS NICD NHLS NICD